<DOC>
	<DOCNO>NCT00002953</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness epirubicin cyclophosphamide epirubicin paclitaxel treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Epirubicin Cyclophosphamide Compared With Epirubicin Paclitaxel Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare activity toxicity epirubicin cyclophosphamide epirubicin paclitaxel patient metastatic breast cancer . OUTLINE : Patients randomize receive either epirubicin cyclophosphamide epirubicin paclitaxel . Each drug combination give every 3 week 6 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 704 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven carcinoma breast metastases No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Menopausal status : Not specify Sex : Female Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN ( great 5 time ULN liver metastasis ) Renal : Not specify Cardiovascular : Ejection fraction within normal range No history cardiac disease include myocardial infarction , cardiac failure angina Other : Not pregnant No prior concurrent malignancy likely interfere protocol treatment comparison PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy adjuvant No prior high dose adjuvant chemotherapy require transplantation Cumulative dose doxorubicin great 300 mg/m2 permit Cumulative dose epirubicin great 400 mg/m2 permit At least 6 month since prior anthracyclines Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>